Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-904 with ketamine challenge in healthy volunteers
NCT05049343Phase 1Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAGE-904 (2 arms), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoints: Auditory Evoked Potential in Single-stimulus Paradigm, Mismatch Negativity and 2 more. Started Sep 2021; status: completed.
02
Drugs
SAGE-904
Beyond the preview
Go deeper on NCT05049343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049343.